203 related articles for article (PubMed ID: 9568482)
1. Kinetics of the P-glycoprotein, the multidrug transporter.
Stein WD
Exp Physiol; 1998 Mar; 83(2):221-32. PubMed ID: 9568482
[No Abstract] [Full Text] [Related]
2. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers.
Ford JM
Eur J Cancer; 1996 Jun; 32A(6):991-1001. PubMed ID: 8763340
[No Abstract] [Full Text] [Related]
3. P-glycoprotein--a mediator of multidrug resistance in tumour cells.
Germann UA
Eur J Cancer; 1996 Jun; 32A(6):927-44. PubMed ID: 8763334
[No Abstract] [Full Text] [Related]
4. Experimental modulation of MRP (multidrug resistance-associated protein)-mediated resistance.
Twentyman PR; Versantvoort CH
Eur J Cancer; 1996 Jun; 32A(6):1002-9. PubMed ID: 8763341
[No Abstract] [Full Text] [Related]
5. Multidrug resistance reversal in childhood malignancies--potential for a real step forward?
Pinkerton CR
Eur J Cancer; 1996 Apr; 32A(4):641-4. PubMed ID: 8695268
[No Abstract] [Full Text] [Related]
6. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).
Guo A; Marinaro W; Hu P; Sinko PJ
Drug Metab Dispos; 2002 Apr; 30(4):457-63. PubMed ID: 11901101
[TBL] [Abstract][Full Text] [Related]
7. Reversing the direction of drug transport mediated by the human multidrug transporter P-glycoprotein.
Sajid A; Lusvarghi S; Murakami M; Chufan EE; Abel B; Gottesman MM; Durell SR; Ambudkar SV
Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29609-29617. PubMed ID: 33168729
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological considerations in the modulation of multidrug resistance.
Fisher GA; Lum BL; Hausdorff J; Sikic BI
Eur J Cancer; 1996 Jun; 32A(6):1082-8. PubMed ID: 8763350
[No Abstract] [Full Text] [Related]
9. Lung resistance-related protein: determining its role in multidrug resistance.
Dalton WS; Scheper RJ
J Natl Cancer Inst; 1999 Oct; 91(19):1604-5. PubMed ID: 10511581
[No Abstract] [Full Text] [Related]
10. Novel mechanisms of drug resistance in leukemia.
Ross DD
Leukemia; 2000 Mar; 14(3):467-73. PubMed ID: 10720143
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein mediated multidrug resistance and its implications for pathology.
Trambas CM; Muller HK; Woods GM
Pathology; 1997 May; 29(2):122-30. PubMed ID: 9213329
[TBL] [Abstract][Full Text] [Related]
12. Transporter molecules in multidrug resistance.
Scheper RJ; Scheffer GL; Flens MJ; van der Valk P; Broxterman HJ; Izquierdo MA
Cytotechnology; 1996; 19(3):187-90. PubMed ID: 8862005
[No Abstract] [Full Text] [Related]
13. Multidrug resistance--a fascinating, clinically relevant problem in bioenergetics.
Pedersen PL
J Bioenerg Biomembr; 1995 Feb; 27(1):3-5. PubMed ID: 7629048
[No Abstract] [Full Text] [Related]
14. Molecular mechanisms of drug resistance in single-step and multi-step drug-selected cancer cells.
Calcagno AM; Ambudkar SV
Methods Mol Biol; 2010; 596():77-93. PubMed ID: 19949921
[TBL] [Abstract][Full Text] [Related]
15. Using purified P-glycoprotein to understand multidrug resistance.
Shapiro AB; Ling V
J Bioenerg Biomembr; 1995 Feb; 27(1):7-13. PubMed ID: 7629053
[TBL] [Abstract][Full Text] [Related]
16. Biology of the multidrug resistance-associated protein, MRP.
Loe DW; Deeley RG; Cole SP
Eur J Cancer; 1996 Jun; 32A(6):945-57. PubMed ID: 8763335
[No Abstract] [Full Text] [Related]
17. Transport of new non-cross-resistant antitumor compounds of the benzoperimidine family in multidrug resistant cells.
Tkaczyk-Gobis K; Tarasiuk J; Seksek O; Stefanska B; Borowski E; Garnier-Suillerot A
Eur J Pharmacol; 2001 Feb; 413(2-3):131-41. PubMed ID: 11226386
[TBL] [Abstract][Full Text] [Related]
18. Characterization and functional reconstitution of the multidrug transporter.
Sharom FJ
J Bioenerg Biomembr; 1995 Feb; 27(1):15-22. PubMed ID: 7629046
[TBL] [Abstract][Full Text] [Related]
19. Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies.
Sonneveld P
Eur J Cancer; 1996 Jun; 32A(6):1062-9. PubMed ID: 8763348
[No Abstract] [Full Text] [Related]
20. Use of shape similarities for the classification of P-glycoprotein substrates and nonsubstrates.
Schwaha R; Ecker GF
Future Med Chem; 2011 Jul; 3(9):1117-28. PubMed ID: 21806376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
